Navigation Links
BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
Date:11/1/2012

LYNBROOK, N.Y., Nov. 1, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, announced today that it will host a conference call and live audio webcast at 4:30 p.m. EST on Thursday, November 8, 2012 to report its third quarter 2012 financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com or you may use the link: http://www.videonewswire.com/event.asp?id=90670.

A replay of the call will be available one hour after the end of the conference on November 8, 2012 until 9:00 a.m. EST on November 23, 2012. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10020975. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Currently, injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is also in clinical development for the treatment of several additional promising indications. Auxilium has reported positive top-line results from two recently completed Phase III clinical trials for Peyronie's disease and is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials.  Auxilium has entered into three strategic partnerships for development and commercialization outside the U.S. of injectable collagenase for Dupuytren's contracture and Peyronie's disease. Pfizer Inc. has rights in Europe and Eurasia and injectable collagenase is currently marketed as XIAPEX® for Dupuytren's contracture in select European countries. Asahi Kasei Pharma Corporation has rights in Japan and Actelion Pharmaceuticals Ltd. has rights in Canada, Australia, Brazil and Mexico. For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
5. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
6. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
7. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
8. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
9. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
10. BioStorage Technologies to Lead Discussion on the Value of a Comprehensive Sample Management Strategy
11. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD announces that AB Laboratories Inc. ... its licensed production facility under the Access to Cannabis ... Hamilton, Ontario . The facility, ... October 2016, is currently operating at half capacity, with ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 /PRNewswire/ ... the NASDAQ Composite ended the trading session at ... edged 0.03% lower, to finish at 20,661.30; and ... 0.19%. Gains were broad based as six out ... This Thursday, Stock-Callers.com has initiated reports coverage on ...
(Date:3/23/2017)... Mass. , March 23, 2017 Merrimack ... enrollment of its first patient in a Phase 1 ... antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and ... is overexpressed in 50-100% of many major tumor types, ... "The initiation of this study is an ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... ... program owned and organized by HMP Communications Holdings, LLC, today announced that ... within its nationwide network of wound centers interested in becoming Certified Wound Specialist ...
(Date:3/23/2017)... ... March 23, 2017 , ... March ... that enables organizations to easily reprint customer invoices, bills, statements and other correspondence ... of the steps needed to retrieve and print the documents and batch them ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... Angeles, CA (PRWEB) , ... March 23, 2017 , ... ... of all Americans, yet poor sleep is likely not the only cause of the ... undesirable characteristics that make you look older or in poor health are likely due ...
(Date:3/23/2017)... ... ... Inflow IQ & Inflownomics of Raleigh, NC introduce a powerful information access ... As experts in dangerous situations the Inflow IQ team can help people. Get ... clean & refreshing knowledge systems that enhance life. , Authentically enjoy ...
Breaking Medicine News(10 mins):